Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER |
| 1 |
| Dec 20, 2024 |
| clinicaltrials |
| NCT06745427 | A Multi-center Prospective Study on the Oncological and Reproductive Outcomes and Quality of Life in Young Woman After Fertility-sparing Treatment of Endometrial Cancer and Endometrial Intraepithelial Hyperplasia(PreFerEC/EIN) | not yet recruiting | — | 100 | Region StockholmOTHER_GOV | 0 | Dec 20, 2024 | clinicaltrials |
| NCT06649838 | Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions | not yet recruiting | — | 60 | Peking Union Medical College HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06737640 | Evaluation of Clinical and Molecular Biomarkers in Immunotherapy Treatment in Gynecologic Cancer(Immuno-Gyn) | not yet recruiting | — | 90 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | not yet recruiting | Phase 2 | 79 | Fudan UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06673511 | The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian Cancer | not yet recruiting | N/A | 246 | Anhui Provincial HospitalOTHER_GOV | 0 | Nov 21, 2024 | clinicaltrials |
| NCT06553742 | High Definition Profiling of Ovarian Cancer Ascites | not yet recruiting | — | 50 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06681636 | Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure(HPV9vxFSW) | not yet recruiting | Phase 2 | 300 | National Institute of Hygiene and Epidemiology, VietnamOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06672341 | Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation | not yet recruiting | — | 200 | Yulan RenOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06665841 | Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes(SeHPV) | not yet recruiting | — | 200 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06662708 | Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer | not yet recruiting | N/A | 200 | Shao PengfeiOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS) | not yet recruiting | Phase 2 | 40 | British Columbia Cancer AgencyOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06640738 | Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation | not yet recruiting | Phase 4 | 60 | Kaohsiung Medical UniversityOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06634173 | The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer(proFAPI) | not yet recruiting | N/A | 30 | The Netherlands Cancer InstituteOTHER | 0 | Oct 9, 2024 | clinicaltrials |
| NCT06619743 | HPV Infection and Vaginal Microecology in Immunosuppressed Women | not yet recruiting | — | 10,000 | Lan ZhuOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06617585 | The Role of CircDENND4C in Epithelial Ovarian Cancer | not yet recruiting | — | 30 | Assiut UniversityOTHER | 0 | Sep 27, 2024 | clinicaltrials |
| NCT06591078 | Evaluation of Clinical Efficacy of Acupuncture in Improving Immune Response in Patients With Cervical Cancer | not yet recruiting | N/A | 90 | Ying ZhangOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06594471 | Comprehensive Assessment of Clinical Characteristics and Outcomes of Gemelli Adolescents and Young Adults(G-AYA) | not yet recruiting | — | 500 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600841 | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer | not yet recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06582108 | UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT(ROAR) | not yet recruiting | — | 190 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06576362 | Evaluation of Ultrasound-guided Transuterine Vaginal Biopsy Technique in Uterine Fibromatous Disease(EFIBIA) | not yet recruiting | N/A | 250 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06524219 | Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery. | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 19, 2024 | clinicaltrials |
| NCT06557954 | Cervical Cytology DNA Methylation for Cervical Cancer Screening | not yet recruiting | — | 30,000 | Lei LiOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06558019 | Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence | not yet recruiting | — | 509 | Lei LiOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06541171 | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results(FOFU) | not yet recruiting | — | 220 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06283875 | The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | not yet recruiting | — | 80 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06501417 | EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome(EC_ItaLynch) | not yet recruiting | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06489496 | Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial(PAX) | not yet recruiting | — | 1,000 | Alberta Health servicesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06453785 | Comparing pOrtable MRI and TRUS-Fusion Prostate Biopsy to Assess aCcuracy of Prostate Cancer Detection(IP10-COMPACT) | not yet recruiting | N/A | 85 | Imperial College LondonOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06442605 | Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy | not yet recruiting | N/A | 22 | First People's Hospital of HangzhouOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06435702 | Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study | not yet recruiting | — | 108 | Peking University Third HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06430411 | Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study(OLIGOMET) | not yet recruiting | — | 500 | Medical University of ViennaOTHER | 0 | May 28, 2024 | clinicaltrials |
| NCT06426056 | Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. | not yet recruiting | Phase 2 | 64 | Peking University Third HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials